In the fourth quarter, reported a 68% increase in revenue to $71.5 million as adjusted EPS jumped to $0.13 from $0.11 in the previous year. Growth came from acquisitions, such as assets from Kilitch Drugs in India, which expanded its generic injectable line, as well as from selling more organic compounds. What's more, these results were on top of the downtime caused by Hurricane Sandy at its ophthalmic factory in New Jersey..Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha).

It doesn't get any simpler than good vs. Evil and right now there is just way too much gray area and confusion. Every character doesn't need more emotional baggage in their life under the semblance of giving them depth.Look at a map of the world. Check where in that big geography the oil is. What a